Loading...
•
Jun 30, 2021
Evofem Biosciences Q2 2021 Earnings Report
Reported strong growth in Phexxi prescriptions and dispensed units.
Key Takeaways
Evofem Biosciences reported a 68% increase in Phexxi net product sales, reaching $1.9 million, alongside a decrease in total operating expenses by 6%. The company's net loss attributable to common stockholders improved to $33.4 million, or $(0.27) per share.
Phexxi prescriptions filled increased by 47% compared to Q1 2021.
Dispensed units increased by 65% compared to Q1 2021.
Prescriber base grew by 61% in Q2 2021 compared to Q1 2021.
National brand ambassador campaign is launching in September 2021.
Evofem Biosciences
Evofem Biosciences
Forward Guidance
Evofem is on track to complete enrollment in EVOGUARD by year-end 2021 and expects cost containment measures to result in aggregate savings of $9.5 million on an annualized basis.
Positive Outlook
- Strong and sustainable growth in Phexxi prescriptions.
- Strong and sustainable growth in dispensed units.
- Momentum allows to further accelerate the growth trajectory with celebrity campaign launching in early September.
- On track to complete enrollment in EVOGUARD by year-end 2021.
- Cost containment measures are expected to result in aggregate savings of $9.5 million on an annualized basis.